tradingkey.logo

BRIEF-Bristol-Myers Squibb Co Says New Five-Year Sotyktu (Deucravacitinib) Data Show Consistent Safety And Durable Response Rates In Moderate-To-Severe Plaque Psoriasis

ReutersFeb 16, 2025 12:04 PM

- Bristol-Myers Squibb Co BMY.N:

  • BRISTOL-MYERS SQUIBB CO - NEW FIVE-YEAR SOTYKTU (DEUCRAVACITINIB) DATA SHOW CONSISTENT SAFETY AND DURABLE RESPONSE RATES IN MODERATE-TO-SEVERE PLAQUE PSORIASIS

Source text: ID:nBw89WLb6a

Further company coverage: BMY.N

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI